Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Lu Lu and Lanying Du.
Connection Strength

1.669
  1. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020 Apr; 30(4):343-355.
    View in: PubMed
    Score: 0.219
  2. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019 04; 5(4):eaav4580.
    View in: PubMed
    Score: 0.204
  3. A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. Nat Commun. 2017 07 25; 8:15672.
    View in: PubMed
    Score: 0.182
  4. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets. 2017 Feb; 21(2):131-143.
    View in: PubMed
    Score: 0.174
  5. Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res. 2015 Apr 16; 202:151-9.
    View in: PubMed
    Score: 0.151
  6. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol. 2013 Sep; 87(17):9939-42.
    View in: PubMed
    Score: 0.137
  7. Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect. 2013 Jul-Aug; 15(8-9):625-9.
    View in: PubMed
    Score: 0.137
  8. Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Emerg Microbes Infect. 2017 Oct 11; 6(10):e89.
    View in: PubMed
    Score: 0.046
  9. HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. Emerg Microbes Infect. 2017 Jun 21; 6(6):e59.
    View in: PubMed
    Score: 0.045
  10. Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains. J Infect. 2017 07; 75(1):68-71.
    View in: PubMed
    Score: 0.044
  11. Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. J Virol. 2016 01 01; 90(1):57-67.
    View in: PubMed
    Score: 0.040
  12. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. Sci Rep. 2015 Aug 19; 5:13028.
    View in: PubMed
    Score: 0.040
  13. Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection. J Infect Dis. 2015 Dec 15; 212(12):1894-903.
    View in: PubMed
    Score: 0.039
  14. Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother. 2015 Jan; 59(1):742-4.
    View in: PubMed
    Score: 0.037
  15. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014 Dec 19; 194:200-10.
    View in: PubMed
    Score: 0.037
  16. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014 Jul; 88(14):7796-805.
    View in: PubMed
    Score: 0.036
  17. Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis. 2013 Aug; 5 Suppl 2:S142-8.
    View in: PubMed
    Score: 0.034
  18. Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4. J Infect. 2013 Aug; 67(2):156-8.
    View in: PubMed
    Score: 0.034
  19. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PLoS One. 2012; 7(5):e37019.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.